A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy

• Status: Completed
• Trial end date: 2007-03-31
• Target enrollment: 0
• Participant gender: Female

Summary

This study will evaluate the efficacy and safety of subcutaneous (SC) epoetin beta in anemic participants with breast cancer undergoing chemotherapy.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Epoetin Alfa

Criteria

Inclusion Criteria:

• Adult female participants with histological diagnosis of breast cancer

• Any type of chemotherapy planned for greater than or equal to (>/=) 9 weeks

• Hemoglobin level less than (<) 11 grams per deciliter (g/dL)

• Participants able to receive iron supplement, if necessary

Exclusion Criteria:

• Known or suspected contraindications to epoetin beta

• Pregnancy or lactation period

• Diagnosis of anemia only due to iron-deficiency

• Diagnosis of thalasemic syndromes

• Epilepsy and/or cerebral metastasis

• Blood transfusion or treatment with any erythropoietic factor within 4 weeks before study start